With a focus on setting up tissue processing centers throughout the United States, IntelliCell BioSciences, Inc., a company in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, has signed an agreement to open an Adipose Stem Cell Processing Center in Houston, Texas in the next six weeks.
According to a press release, this center will make adipose derived stem cells available for doctors in the metro Houston area.
In the aesthetic world, the use of autologous adipose stem cells has become accepted in Europe and Asia. Since the middle of 2009 when the US FDA published its laws on autologous stem cells the field has expanded rapidly. Currently, numerous doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments.
"We believe IntelliCell is setting the gold standard for adipose stem cell processing. Our technology provides stem cell counts and viability checks for each specimen processed, as well as documents the quality and quantity of the stem cells produced. Management believes the Company's entry into the Houston market will grant us the opportunity to offer this community of physicians, researchers, and healthcare centers access to the highest number and quality stromal vascular fraction (SVF) cells which contain adult stem cells through our proprietary, FDA compliant process. We are very pleased to see Houston receive this promising service," stated IntelliCell Chairman and CEO, Dr. Steven Victor.
IntelliCell's adipose stem cell processing technique takes approximately 30 minutes and the stem cells can be returned to the doctor in the same day. The company has developed an in-house technology where it can easily process stromal vascular cells containing a high concentration of adipose stem cells with excellent viability.
IN other company news, HealthTechZone reported that IntelliCell BioSciences Inc. signed a definitive Agreement and Plan of Merger with Media Exchange Group.
Mandira Srivastava is a HealthTechZone contributor. She works as a full-time writer, ghostwriter and blogger, and has more than two years of experience in print and Web media. She has also worked on company brochures, website content and product descriptions, as well as proofreading and editing content. To read more of her articles, please visit her columnist page.Edited by
Rich Steeves
